Aug. 28 P&P Quick Takes: Liver failure warning for HCV drugs; plus FDA guidances and more

Liver failure linked to HCV drugs
FDA said it has identified 63 incidences of worsening liver function, including cases of liver failure and death, in patients with liver impairment taking HCV drugs Mavyret glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV), Zepatier

Read the full 381 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE